Postmenopausal Hormone Therapy and Systemic Lupus Erythematosus
Authors: Jean-Charles Piette
Journal: Annals of Internal Medicine (1995)

Letters15 December 1995Postmenopausal Hormone Therapy and Systemic Lupus ErythematosusJean-Charles Piette, MD, Le Thi Huong Du, MD, and Thomas Papo, MDJean-Charles Piette, MDGroupe Hospitalier Pitie-Salpetriere, 75013 Paris, FranceSearch for more papers by this author, Le Thi Huong Du, MDGroupe Hospitalier Pitie-Salpetriere, 75013 Paris, FranceSearch for more papers by this author, and Thomas Papo, MDGroupe Hospitalier Pitie-Salpetriere, 75013 Paris, FranceSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-12-199512150-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Sanchez-Guerrero and colleagues [1] reported that postmenopausal estrogen replacement therapy increases the risk for developing systemic lupus erythematosus. Some unmentioned confounding factors related to the nurses' medical histories should be discussed.The risk might have been underestimated because a history of thrombosis could have discouraged physicians from prescribing estrogen replacement therapy. Some of these thromboses may have been related to an unrecognized antiphospholipid syndrome, which sometimes precedes full-blown systemic lupus erythematosus [2].However, the risk may have been overestimated because of the possible inclusion of nurses with other autoimmune but nonrheumatic disorders for which estrogen replacement therapy ...References1. Sanchez-Guerrero Jorge, Liang Matthew H., Karlson EW, Hunter DJ, Colditz Graham A.. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-3. LinkGoogle Scholar2. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992;21:275-86. CrossrefMedlineGoogle Scholar3. Moncayo-Naveda H, Moncayo R, Benz R, Wolf A, Lauritzen C. Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol. 1989;160:1227-9. CrossrefMedlineGoogle Scholar4. Blumenfeld Z, Halachmi S, Peretz BA, Shmuel Z, Golan D, Makler A, et al . Premature ovarian failure—the prognostic application of autoimmunity on conception after ovulation induction. Fertil Steril. 1993;59:750-5. CrossrefMedlineGoogle Scholar5. Case records of the Massachusetts General Hospital. Case 46-1986. A 26-year-old woman with secondary amenorrhea. N Engl J Med. 1986; 315:1336-43. Google Scholar Author, Article, and Disclosure InformationAffiliations: Groupe Hospitalier Pitie-Salpetriere, 75013 Paris, France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMénopause et maladies systémiquesCan we advise ovulation induction in patients with SLE?Immunosuppressive Drugs in Cutaneous Lupus Erythematosus 15 December 1995Volume 123, Issue 12Page: 961-962KeywordsAntibodiesEstrogen replacement therapyHormone replacement therapyLupus erythematosusOvariesRheumatologyRisk managementSteroidsSystemic lupus erythematosusThrombosis ePublished: 15 August 2000 Issue Published: 15 December 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...